FDA advisory panel backs Grail's Galleri blood cancer test in landmark vote

A panel of outside FDA experts voted 7-2 (with one abstention) that the benefits of Grail's Galleri blood-based multi-cancer detection test outweigh its risks for adults aged 50 and older — a significant milestone on the path to potential FDA approval. While the committee was unanimous on safety, it split 6-4 on whether the evidence sufficiently demonstrated effectiveness.

Analysts are optimistic. Guggenheim's Subbu Nambi called the vote "almost derisked," predicting the FDA will ultimately approve Galleri for a wide range of cancers. The FDA isn't bound by its advisory panel's votes but typically weighs them heavily — a final decision is expected within months.

By the Numbers:

• 7-2 — panel vote endorsing benefits over risks
• 6-4 — split vote on efficacy evidence
• 35% — cancers detected within 12 months in a U.S. study of 25,490 people
• 99.85% — specificity rate, indicating a very low false-positive rate
• 50+ — cancer types screened from a single blood draw

Why it matters: FDA approval would mark a paradigm shift in cancer screening, potentially enabling Medicare coverage for eligible patients from 2029. Experts stress Galleri should complement — not replace — proven screenings like mammograms and colonoscopies.